Member Meeting to Discuss Cannabis-Derived Products Programming
Dear FDLI Members,
FDLI invites your input, as an FDLI member, on the development of new programming and the constitution of a committee for cannabis-derived products.
As you may be aware, cannabis-derived products are a growing area of interest for practitioners and stakeholders across many areas of FDA regulation. Although illegal at the federal level (with the exception of the recent narrow carve-out for Epidiolex) these products and related businesses are multiplying under state legalization regimes and global liberalization. This reality poses numerous challenges and opportunities for FDLI members.
We invite you to a FDLI member meeting to brainstorm about how FDLI might proceed in the cannabis-derived product space. The meeting will be held on November 2 from 4:15 – 5:00 PM, immediately following our Symposium event. Please consider joining us for the Symposium focused on federal regulation of cannabis, but if unable, we hope you will still join the meeting. A reception will follow. If you do not plan to attend the Symposium but wish to attend the member meeting, please sign up so that your name can be included on the security list.
If you are unable to attend this meeting but have thoughts you wish to share on the topic, please email FDLI’s Director of Publications, Judy Rein, at [email protected].
We look forward to a lively and informative discussion and appreciate the FDLI member community’s engagement with this new area of programming.
Amy Comstock Rick
President & CEO
FOOD AND DRUG LAW INSTITUTE
1155 15th Street NW, Suite 910
Washington, DC 20005
202-371-1425 I www.fdli.org
A Membership Organization Engaging the Food and Drug Law Community